SCHEMBL4909099

SCHEMBL4909099

O=C(NCCCCO)c1cccc(Br)c1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.72
L3MBTL1 Q9Y468 1/20 0.69
TP53BP1 Q12888 1/20 0.66
NPC1 O15118 1/20 0.62
RAB9A P51151 1/20 0.62
TMEM97 Q5BJF2 1/20 0.61
SIGMAR1 Q99720 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.59
HDAC1 Q13547 1/20 0.56
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPT P10636 3/20 0.52
ALDH1A1 P00352 2/20 0.52
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
POLB P06746 1/20 0.51
CYP2C9 P11712 1/20 0.51
NAAA Q02083 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9491289 0.92 LMNA (0.83) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL1663227 0.89 L3MBTL1 (0.76) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL31055438 0.86 L3MBTL1 (0.82) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL5657260 0.84 LMNA (1.00) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL9717416 0.83 SMN1; SMN2 (0.71) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL12760642 0.82 L3MBTL1 (0.67) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL1928397 0.82 L3MBTL1 (1.00) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL6290094 0.82 L3MBTL1 (0.76) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL4914982 0.82 L3MBTL1 (0.66) LMNAL3MBTL1TP53BP1NPC1RAB9A
SCHEMBL10604330 0.82 L3MBTL1 (0.70) LMNAL3MBTL1TP53BP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof SIENA BIOTECH S.P.A. (IT) 2008-11-06 US disclosed
CN-101018774-A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof SIENA BIOTECH SPA (IT) 2007-08-15 CN disclosed
EP-1778658-A2 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF Siena Biotech S.p.A. (IT) 2007-05-02 EP disclosed
WO-2006008133-A2 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF SIENA BIOTECH S.P.A. (IT) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275028-A1 Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof CHRNA7, CHRNA5, CHRNA1 LMNA 3535/4885L3MBTL1 3654/4885TP53BP1 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.